STOCK TITAN

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
89bio to participate in H.C. Wainwright NASH Investor Conference
Positive
  • 89bio, Inc. will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023.
  • Investors can access the webcast of the presentation on 89bio's website.
Negative
  • None.

SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference being held on Tuesday, October 24, 2023.

Presentation details are as follows:
Format: Fireside chat
Time: 11:30 AM ET

The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Annie Chang
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com


FAQ

What is the purpose of 89bio's participation in the H.C. Wainwright NASH Investor Conference?

89bio will participate in a fireside chat and one-on-one investor meetings at the conference.

When will the presentation take place?

The presentation will take place at 11:30 AM ET on October 24, 2023.

Where can investors access the webcast of the presentation?

Investors can access the webcast on 89bio's website.

89bio, Inc.

NASDAQ:ETNB

ETNB Rankings

ETNB Latest News

ETNB Stock Data

849.05M
69.50M
0.86%
106.21%
12.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About ETNB

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.